GlassScriptPhysician profile
Yasemin Osman
NPI 1316991037
$8,605.89
in general payments reported to CMS, 2019-2025
31 companies · $1,568 in 2025
The $1,568 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,122 · 2020: $548 · 2021: $870 · 2022: $1,328 · 2023: $1,403 · 2024: $1,768 · 2025: $1,568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,373 · Education: $366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,372.52 |
| Education | $365.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,142.23 | 2020-2025 | Tremfya, Simponi, Simponi Aria |
| Abbvie INC. | $853.20 | 2019-2025 | |
| Incyte Corporation | $780.01 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $757.41 | 2019-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $746.13 | 2019-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $552.85 | 2020-2025 | Winlevi |
| Lilly USA, LLC | $534.02 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $487.06 | 2019-2025 | |
| Pfizer INC. | $374.53 | 2019-2025 | |
| Dermavant Sciences, INC. | $335.81 | 2023-2024 | Vtama |
| Mayne Pharma Commercial LLC | $223.73 | 2019-2020 | |
| Merz North America, INC. | $220.38 | 2019-2024 | |
| Arcutis Biotherapeutics, INC. | $187.30 | 2023-2024 | Zoryve |
| Amgen INC. | $181.35 | 2020-2022 | |
| Ucb, INC. | $172.17 | 2019-2025 | Bimzelx |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $147.74 | 2019-2025 | |
| Sandoz INC. | $137.15 | 2019-2021 | |
| Almirall LLC | $129.29 | 2019-2025 | Klisyri, Seysara |
| Botanix Sb INC | $104.60 | 2025 | Sofdra |
| E.R. Squibb & Sons, L.L.C. | $101.14 | 2022-2024 | Sotyktu |
| Epi Health, LLC | $90.34 | 2019-2021 | |
| Organon LLC | $75.07 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $47.65 | 2020-2021 | |
| Cipher Pharmaceuticals US LLC | $44.04 | 2025 | Spinosad, Natroba |
| Dermira, INC. | $31.66 | 2019 | |
| Sebela Pharmaceuticals INC. | $29.20 | 2022-2023 | Naftin, Pramosone |
| Galderma Laboratories, L.P. | $28.07 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.20 | 2022 | |
| Celgene Corporation | $23.33 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $23.23 | 2019 | |
| Sensus Healthcare, INC. | $19.00 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yasemin Osman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.